cyrilzakka/clinical-trials huggingface dataset:
Pulmonary Infections Masquerading as Community-Acquired Pneumonia

The purpose of this research is to identify cases from patients who have been referred for consultation to the Infectious Disease Section at the VAMC, Houston, and to compare them with other cases of CAP in order to determine whether there are features that might enable non-CAP cases to be distinguished from CAP.

Guidelines to treat community acquired pneumonia (CAP) have been developed and widely promulgated by important professional societies in the past 10 years. The impetus to do so came from the observation that practicing physicians were using a wide array of approaches to this common infection, many of which were substandard.

The Infectious Disease Society of America (IDSA) and American Thoracic Society (ATS) have been leaders in this field, publishing recommendations separately between 1993 and 2003. The PI served on the IDSA committee and coauthored the publication in 2000 and the update in 2003. In 2004, a decision was made by the two professional societies to merge the committees and make a single joint set of recommendations; the PI is a member of that joint committee and a new document is being prepared for publication.

The PI has observed a tendency to apply these guidelines to cases that might masquerade as CAP but are actually attributable to other conditions, such as lung cancer, tuberculosis and histoplasmosis. Further, the recommendations do not adequately cover pneumonia due to Staphylococcus aureus.

The purpose of the research is to identify cases from the consult records of the Infectious Disease Section at the VAMC, Houston, and to compare them with other cases of CAP in order to determine whether there are features that might enable non-CAP cases to be distinguished from CAP.

Eligibility Criteria:
Inclusion Criteria:

* subjects who were seen in calendar year 2004 because they were thought to have CAP, but who, upon further evaluation, plainly did not, and consultation was sought.
* case control is diagnosis of CAP with verification by all or nearly all of the following features: presence of cough, increased sputum, fever, leukocytosis and a distinct new pulmonary infiltrate.

Exclusion Criteria:

* among the case controls, if the diagnosis of CAP was made despite the absence of the cardinal features of CAP, as cited above, the investigators will not include the case.
Self-help in Adjunct to Pharmacotherapy

Therapist-led parenting interventions have been shown to reduce symptoms of attention deficit hyperactivity disorder (ADHD) and are recommended as a first line treatment for school age children with ADHD. However, parenting interventions can be costly and impractical for parents due to factors such as time constraints and travelling costs. A self-help parent training manual has been developed and initial results have shown moderate reductions in ADHD symptoms, indicating that whilst self-help may offer a cost effective alternative to therapist led parent training interventions, it may not be sufficient to treat ADHD alone. This study therefore aims to compare the efficacy and additional benefits of the self-help intervention plus treatment as usual including pharmacotherapy with a control treatment as usual group . Families with a child aged 6-10 with a clinical diagnosis of ADHD will be recruited to the study via referrals from community paediatricians and child and adolescent mental health services. After gaining informed consent subjects will be randomised to self-help plus Treatment as usual (TAU) + or TAU (control). Those allocated to TAU+SH will be issued with the self-help manual and an introductory DVD to highlight key aspects of the intervention. Self-help intervention will last for 12 weeks. Data will be collected via standardised questionnaires completed by the parent, teacher and child and a recorded speech samples from the parent. Data will be collected at three time points; pre-intervention, post-intervention (12 weeks) and as a long term follow up (28 weeks). After completing the trial, qualitative data will be collected about participants' experience of self-help intervention.


Eligibility Criteria:
Inclusion Criteria:

* Parent/Main caregiver aged 18 years or over.
* Children aged been 6-10 years who have received a clinical diagnosis of ADHD.
* Children who are about to commence a course of medication for ADHD for the first time or a currently receiving medication for ADHD.

Exclusion Criteria:

* Parents who are not fluent in English, or unable to read English. (Due to copyright restrictions the self-help manual is only available in English.)
* Families who clinicians feel may be unable/incapable of completing the self-help intervention (e.g. where parents have severe mental illness)
* Parents who are aware that they have had previous experience of the NFPP
Ankle Block Versus Popliteal Fossa Block as Primary Anesthesia for Forefoot Surgical Procedures

The purpose of this study is to compare, for the first time ever, single shot popliteal fossa blocks to ankle blocks as primary anesthesia for patients undergoing forefoot procedures. The primary outcome variable for this study is the percentage of patients that convert to general anesthesia following either a single shot popliteal fossa block or ankle block.

H0: There is no difference in the percentage of patients that convert to general anesthesia between single shot popliteal fossa blocks and ankle blocks.

HA: There will be a lower percentage of patients receiving a single shot popliteal fossa block that convert to general anesthesia compared to patients receiving an ankle block.


Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing elective forefoot surgery, including both soft-tissue and osseous procedures

Exclusion Criteria:

* Diabetes
* Any form of Peripheral neuropathy
* Known allergy to local anesthesia
* Active infection
Hyperbaric Oxygen Therapy for Ulcerative Colitis (HBOT-UC)

Chronic intestinal hypoxia and accompanying mucosal inflammation is a hallmark of ulcerative colitis (UC). Hyperbaric oxygen therapy (HBOT) involves breathing 100% oxygen under increased atmospheric pressure to increase tissue oxygenation. Two small prospective randomized controlled trials have demonstrated that the delivery of HBOT to UC patients hospitalized for acute moderate to severe flares results in improved remission rates and avoidance of in-hospital progression to biologics, small molecules, or colectomy. In this larger trial the study aims to confirm the treatment benefits of HBOT for hospitalized UC patients and study the immune-microbe mechanisms underpinning treatment response.


Eligibility Criteria:
Inclusion Criteria:

* Participants with known or newly diagnosed UC who require hospitalization for an acute moderate to severe flare
* Age 18-85
* Able to fully participate in all aspects of the trial
* Consented and able to receive first HBOT session within first 48 hours of initiation of intravenous steroids
* Agreement to not participate in another trial for the duration of the active intervention period

Exclusion Criteria:

* Received hyperbaric oxygen therapy either as part of standard of care or through a clinical trial prior to enrollment
* Complication requiring urgent surgical intervention
* Requirement for new start of a biologic or small molecule during the hospitalization prior to randomization and/or anticipated requirement for rescue medical or surgical therapy within 48 hours of randomization
* Toxic megacolon
* Inability to receive intravenous steroids
* Historically failed or been exposed to 4 or more classes of advanced therapeutic options
* Known or suspected diagnosis of Crohn's colitis, indeterminate colitis, ischemic colitis, radiation colitis, diverticular disease associated with colitis, microscopic colitis or infectious colitis
* Received any investigational drug within 30 days
* Clinically significant cardiac, renal, neurological, endocrine, respiratory or hepatic impairment that increases the risk for HBOT toxicity
* Women who are pregnant or nursing
* Unwillingness to complete course of HBOT
Effectiveness of Custom-made Foot Orthoses vs Heel Lifts in Children With Calcaneal Apophysitis

The study was a parallel-group, randomized controlled trial with concealed allocation, blinding of investigators and assessors and intention-to-treat analysis. It examined the effect of custom-made foot orthoses and heel lifts in children with calcaneal apophysitis.

It was hypothesized that the primary outcome, pain relief, would be significantly improved with the custom-made orthosis compared to the heel lift.


Eligibility Criteria:
Inclusion Criteria:

* diagnosed radiologically with calcaneal osteochondritis
* diagnosed radiologically with calcaneal osteochondritis
* have signed informed consent

Exclusion Criteria:

* had suffered some trauma on the heel in the past 2 months
* had received anti-inflammatory drugs and/or physical treatment for pain in the past 3 months
* had presented physical or neurological impairment
* were not interested
Determinants of the Level of Anti-SARS-CoV-2 IgG ANTibodiEs After Vaccination Study in Patients After Organ Transplantation

Great expectations to control the pandemic are placed in vaccines against COVID-19. Currently, the four COVID-19 vaccines approved in the European Union. The investigators designed a study assessing the anti-SARS-CoV-2 IgG antibody titer after vaccination cycle with the BNT162b2 vaccine in several time points relating these results to the COVID-19 history and severity of symptoms during the disease and after the first and second vaccine dose.

The study includes patients of Antoni Jurasz University Hospital No.1 in Bydgoszcz after organ transplantation. To meet the inclusion criteria patients will have to be vaccinated with two doses of the BNT162b2 vaccine. The assessment of the anti-SARS-CoV-2 IgG antibody titer at several time points in each participant. Fresh serum samples were used to measure SARS-CoV-2 IgG on the Siemens Atellica system (Siemens Healthineers, Erlangen, Germany). Results of SARS-CoV-2 IgG were given as U/ml, whereby the cut-off for positivity was defined as ≥1.0 U/ml.

Eligibility Criteria:
Inclusion Criteria:

* Provision of informed consent to study
* Age ≥ 18 years
* Receiving two doses of the BNT162b2 vaccine
* patients post organ transplantation

Exclusion Criteria:

* patients who did not complete 2-dose vaccination schedule
* patients who received any other vaccine than BNT162b2
* patients considered by investigator to be unable to cooperate
Muscle Blood Flow During Exercise

Physical exercise triggers various physiological responses including a marked increase in muscle blood flow and oxygen delivery in order to support muscle activity. How muscle blood flow is controlled is currently unclear.

The primary purpose of this study is to establish the respective contribution of metabolic (linked to energy requirements) and mechanical (linked to muscle tensions) signals in the exercise hyperemia and the possible role of the red blood cells.

Vasodilation and muscle blood flow during exercise are controlled by ATP released in the plasma from the red blood cells in response to a combination of metabolic and mechanical signals applied on the vasculature.


Eligibility Criteria:
Inclusion Criteria:

* Non smoker or having stopped smoking for at least 5 yr
* Practice sports: physical activity level will be evaluated with a questionnaire (de Baecke et coll., 1982) and will give an activity index greater than 6 together with a VO2max greater than 50 ml/kg/min
* Body mass index lower than 25
* Registered to the French Social Security system
* Providing a written and informed consent to participate in the study

Exclusion Criteria:

* History of venous or arterial thrombo-embolic events
* Bad perfusion from the cubital artery
* Unable to understand the information notice
* Subject exposed to law investigations or with financial dependancy
* Subjects feeling unwell whan seing blood.
* Subjects advised to not practice sport.
* Musculo-tendinous or articular issues with the lower leg
* Respiratory, cardiovascular or metabolic pathologies
* Current medical treatment that can not be stopped 7 days before the experiment.
Dyslipaemia, Atherosclerosis Risk and Increased hsCRP and Inflammatory and Oxidative Status in the Spanish Population. Database Analysis of Previous Studies Performed in Spain

The present project is aimed at determining the prevalence of LDL-C \<130 mg/dl with hsCRP ≥2mg/l, and of HDL-C \< 40 mg/dl in Spain together with the estimation of cardiovascular risk, to analyze the contribution of measuring hsCRP for primary prevention purposes. In a subgroup of that population a number of inflammatory and oxidative status biomarkers would be also measured to better understand the meaning of elevated hsCRP.The study aim to analyze data already collected in studies (11 studies will participate) carried out in Spain, in 10 Spanish regions, after the year 2000.


Eligibility Criteria:
Inclusion Criteria:

* Have an Informed consent form signed when the patient accepted to participate in the study already performed.
* Spanish population between
* Data from Epidemiological studies performed after the year 2000

Exclusion Criteria:

* Spanish population outside the age range
* Data from Epidemiological studies performed before the year 2000
Efficacy and Safety of Netupitant and Palonosetron Hydrochloride Capsules in Preventing Nausea and Vomiting Induced by Radiochemotherapy in Head and Neck Squamous Cell Carcinoma

The enrolled head and neck squamous cell carcinoma patients in this study received high-dose multiday chemotherapy with cisplatin and synchronous radiation therapy, which had a high risk of nausea and vomiting. On the first and third days, they took Netopitam Palonosetron capsules and dexamethasone to reduce the incidence of acute vomiting. The aim of this study is to evaluate the antiemetic effect of Netopitam Palonosetron capsules and to explore the effectiveness of using Netopitam Palonosetron capsules again for antiemetic treatment during the study period when breakthrough vomiting occurs.


Eligibility Criteria:
Inclusion Criteria:

1. Male or female, aged 18-75 years old;
2. Head and neck tumors confirmed by histology or cytology (including oral cancer, oropharyngeal cancer, hypopharyngeal cancer, and laryngeal cancer);
3. Receive radical synchronous radiotherapy and chemotherapy;
4. The Eastern Oncology Collaborative Group (ECOG) physical fitness score of the subjects was ≤ 2 points;
5. Adequate organ and bone marrow function;
6. The expected life is at least 12 weeks;
7. Pregnant or fertile patients (male or female) use reliable contraceptive measures;
8. When screening female patients with potential pregnancy, the pregnancy test must be negative;
9. The subjects voluntarily and strictly comply with the requirements of the research protocol and sign a written informed consent form.

Exclusion Criteria:

1. Recurrent and metastatic head and neck tumors;
2. Previously underwent tumor resection surgery for treatment;
3. Patients with platinum drug intolerance;
4. Receiving any known or potential antiemetic medication within 24 hours prior to the first day, or experiencing symptoms of vomiting, retching, or mild nausea within 24 hours prior to the first day;
5. Take NK1（neurokinin-1） receptor antagonists or any study medication within 4 weeks before the start of the experiment;
6. Use CYP3A4 inducer within 4 weeks before chemotherapy, and use CYP3A4 substrate or strong or moderate CYP3A4 inhibitor within 1 week;
7. Serious cardiovascular, pulmonary, diabetes, mental and other diseases;
8. Pregnant or lactating women, patients with fertility who are unwilling or unable to take effective contraceptive measures;
9. Drug and/or alcohol abuse;
10. Hypocalcemia or any other condition that may cause vomiting;
11. There are significant factors that affect the absorption of oral medication, such as chronic diarrhea and intestinal obstruction;
12. The subject has allergic reactions to Netopitam Palonosetron capsules or any of their excipients;
13. Within 30 days prior to the baseline visit, the subject participated in another clinical study and used any exploratory drugs or devices; Allow participation in observational research;
14. The researcher determines other situations that may affect the progress of clinical research and the determination of research results.
Does Using a Low Vision Aid Device Improve Quality of Life in Glaucoma Patients?

To determine the impact of OrCam over 1 month on health-related quality of life (HRQoL) in subjects with advanced glaucoma using the National Eye Institute Visual Function Questionnaire 25 (NEI-VFQ-25).

To identify tasks for which subjects are using the OrCam device and patient satisfaction.

Participants will document their daily impression about the use of OrCam, a small camera attached to their glasses over a 1-month period. They will attend 2 appointments at Wills Eye Hospital Glaucoma Research Center (baseline and final visit). Participant's will be trained to use the OrCam device at baseline visit and complete a best-corrected visual acuity assessment ETDRS (early treatment diabetic retinopathy study) and the NEI-VFQ-25 questionnaire. They will also read a short newspaper article.

The NEI-VFQ-25 includes a series of 25 questions pertaining to vision or feelings about a vision condition. Answers are selected among a numbered list of possible responses, the values of which are ultimately recoded and converted to a 0 to 100 scale. Items within each subscale are averaged together to create 12 subscale scores. An overall composite score will be calculated by averaging vision-targeted subscale scores, excluding the general health rating question.

Participants will read a short article. They will be asked to grade their reading difficulty between 1 (unable to read) to 10 (able to read without difficulty). Time to read article will be recorded. Reading task will be performed with best correction - with and without the assistance of the OrCam device.

Subjects will utilize OrCam daily for one month. Each week, subjects will record thoughts about the device in a log book or by using audio tape recorder, according to patient's personal preference.

Final assessment at 1 month will include best-corrected visual acuity (ETDRS), NEI-VFQ-25, and the newspaper-reading task with and without OrCam assistance. A satisfaction questionnaire will be completed in order to assess subjects' overall feelings regarding OrCam. Audio log books will be analyzed for specific factors and recorded by a research assistant.

Eligibility Criteria:
Inclusion Criteria:

* Glaucoma any type, characterized by glaucomatous optic neuropathy and corresponding visual field (VF) defect
* Visual acuity of 20/400 to hand motion (HM) in better eye or visual field less than 10 degrees in better eye and having difficulty reading.
* Age 18 years or older
* Able to understand and speak English
* Able to use an electronic recording device
* Able to operate a computerized system

Exclusion Criteria:

* Neurological or musculoskeletal problems that would influence performance on activities of daily living
* Incisional eye surgery within past three months
* Laser therapy within previous month
* Any cause for visual impairment other than glaucoma
* Photophobia
* Any medical condition precluding subject from providing reliable, valid data
Study of Perinatal Transmission of Zidovudine-Resistant HIV Among Pregnant Women Treated With Zidovudine

To identify patterns of zidovudine ( AZT ) susceptibility among mother/infant pairs with perinatal HIV transmission.

Most HIV-infected infants acquire their disease via perinatal transmission. Since transmission of HIV-resistant strains to infants could alter the course of disease and response to currently recommended treatment, a study to assess the patterns of AZT susceptibility among mother/infant pairs with perinatal transmission is essential to delineate future therapeutic strategies.

Most HIV-infected infants acquire their disease via perinatal transmission. Since transmission of HIV-resistant strains to infants could alter the course of disease and response to currently recommended treatment, a study to assess the patterns of AZT susceptibility among mother/infant pairs with perinatal transmission is essential to delineate future therapeutic strategies.

HIV-infected pregnant women are enrolled at 20-36 weeks gestation. Patients have blood drawn for HIV culture at study entry and at delivery. Infants have blood drawn for HIV culture at delivery and at 1, 3, 6, and 18 months of age.

Eligibility Criteria:
Inclusion Criteria

Prior Medication: Required:

* At least 6 months of prior AZT, including continuously during the current pregnancy.

Patients must have:

* HIV seropositivity.
* CD4 count \<= 300 cells/mm3.
* Gestational age of 20-36 weeks, with intention to carry pregnancy to term.
* At least 6 months of prior AZT therapy, including continuous AZT therapy during the current pregnancy.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

* Evidence of pre-existing fetal anomalies that would preclude survival to the end of the study, such as anencephaly, renal agenesis, or Potter's syndrome.

Concurrent Medication:

Excluded:

* Antiretrovirals other than AZT.
The Effect of Milnacipran in Patients With Fibromyalgia

Use of the drug Milnacipran will reduce ventricular lactate levels and processing time for completing complex tasks relative to placebo.

Patients with Fibromyalgia will show elevated ventricular lactate levels as measured via magnetic resonance spectroscopy (MRS). Patients treated with Milnacipran will show normalization of ventricular lactate levels compared to those treated with placebo, and will also show normalization of the increased latency to respond to complex reaction time probes compared to those treated with placebo.

Eligibility Criteria:
Inclusion Criteria:

* Female or male subjects who fulfill the American College of Rheumatology's case definition for Fibromyalgia.
* 18 through 68 years of age

Exclusion Criteria:

* Pregnant or trying to become pregnant
* Taking any other Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or already taking milnacipran
* Patients who do not indicate their pain levels as less than substantial despite their best care
* History of any psychotic disorder or history of alcoholism or drug abuse within 10 years of intake as determined by psychiatric diagnostic interview
* Presence of current depression as determined by psychiatric diagnostic interview
* Presence of brain lesion on MRI anatomical study